Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...

Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The U.S. Food and Drug Administration has approved Regeneron Pharmaceuticals' Lynozyfic, a therapy for recurrent multiple myeloma, boosting the company's shares by 2%.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.

ROCHESTER, Minn. (KTTC) – A Winona industrial supply company provided assistance to a Wisconsin high school student’s science ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s ...

The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. surprised health and privacy experts when he announced June 24 that his agency would launch a massive advertising campaign to encourage ...

The Business Research Company's The Specific Antiviral Drugs For COVID 19 Market Forecast To 2034 – For Business Leaders, Analysts, And Strategic Teams It will grow to $28.43 billion in 2029 at a ...